Hangzhou Tigermed Consulting 泰格医药
23 significant filings since 1 Jun 2026: 1 on detention or investigation, 11 on buyback and 9 on equity incentive, and 2 other kinds. The latest, on 23 Sep 2026: 关于2026年A股限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告.
自 1 Jun 2026 起有 23 份重大公告：detention or investigation 1 份、buyback 11 份、equity incentive 9 份，另有 2 类。最新一份（23 Sep 2026）：关于2026年A股限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告。
Price History 价格走势
3,290 trading days 个交易日 · High 最高 ¥197.53 · Low 最低 ¥3.76The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 9 Apr 2024 | 西南证券 | 杜向阳 | Outperform 增持 | ▲ | Buy 买入 |
| 31 Mar 2021 | 群益证券 | 王睿哲 | Buy 买入 | ▼ | Outperform 增持 |
| 30 Mar 2021 | 国元证券 | 刘慧敏 | Outperform 增持 | ▲ | Buy 买入 |
| 29 Apr 2020 | 华金证券 | 周新明,王睿 | Buy 买入 | ▼ | Outperform 增持 |
| 17 Apr 2020 | 西南证券 | 朱国广,杜向阳 | Buy 买入 | ▼ | Outperform 增持 |
| 21 Feb 2019 | 民生证券 | 钟奇,袁中平 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 3 Sep 2026 | 2 | — |
| 东吴证券 | 朱国广 | Buy 买入 | 15 Feb 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。